The final results of the second round of the health care drug negotiations were finally unveiled in the morning of July 19, 2007. The ministry of human resources has officially released the results of the access negotiation to the medical insurance catalogue. The printing on the 36 kinds of drugs should be brought into the national basic medical insurance, inductrial injury insurance and maternity insurance drug catalogue b range of notice, according to the lalu peptide injection of 36 kinds of drugs into the negotiations of the national basic medical insurance, inductrial injury insurance and maternity insurance drug catalogue (2017 edition) "b class scope, and synchronous identified these drugs to pay for health care standards.
List of 36 drugs
, announced in April this year people club department 44 to negotiate drug list, after negotiation with the relevant enterprises, of which 36 drug negotiations success, the success rate of 81.8%, compared with the average retail price of 2016, negotiations and drug average decline reached 44%, the highest reached 70%, most of the imported drugs after negotiation payment standard is lower than the surrounding international market prices, greatly reduced the medical burden of patients in our country.
Similar to what was previously known, the second round of national health care negotiation varieties eventually included 36 drugs in the drug catalog. It includes 31 western medicines and 5 intermediate medicines. Has 15 is in tumor therapy of western medicine, covered with lung cancer, gastric cancer, breast cancer, colorectal cancer, lymphoma, myeloma and other cancer types, from health care payment standards, released by bead sheet resistance injection (medical insurance payment standard is 7600 yuan (440 mg (20 ml)/bottle)), rituxan injection (medical insurance payment standard is 2418 yuan (100 mg/ml/bottle) 10, 8289.87 yuan (500 mg / 50 ml/bottle), boron injection for Mr M (medical insurance payment standard is 6116 yuan (3.5 mg/bottle), 2344.26 (1 mg/bottle)), the drug lenalidomide oral often release dosage forms (medical insurance payment standard is 866 yuan (10 mg/tablet) and 1101.99 yuan (25 mg/tablet)), and other social comparison attention, ginseng protect personnel demand urgent tumor targeted drugs price decline is bigger, other respectively for the treatment of cardiovascular disease, kidney disease, eye disease, psychosis, anti-infection, major diseases such as diabetes or chronic diseases drugs, as well as the treatment of hemophilia Ⅶ human recombinant coagulation factor a and treatment of multiple sclerosis of human recombinant interferon beta 1 b two kinds of rare diseases.
Three of the drugs were antitumor drugs, and the other two were cardiovascular drugs. In addition, health care medicine directory access negotiations fully embodies the recognition and support of pharmaceutical innovation, included in the scope of negotiations of the west of the amine, compaq heap, path for Nepal and other countries major drug discovery special drugs all negotiations success. Reporter noticed that, like the same limit to wet age-related macular degeneration patients over 50 years of age use compaq heap eye ophthalmic injection published health insurance payment standard is 5550 yuan (0.2 ml/branch of 10 mg/ml), while the negotiations successful licensed resistance injection payment standard is 5700 yuan (0.2 ml / 10 mg/ml, 10 mg/ml of 0.165 ml/branch (prefi lled)), the industry is not difficult to infer that, within the scope of health care in hand-to-hand combat will be intensified.
According to the requirements, the department of social insurance of the provinces (autonomous regions and cities) shall not transfer the relevant drugs to the catalog or adjust the scope of payment. In addition, schedule "medicare payment standard" includes payment standard stipulated in the basic medical insurance fund and ginseng protect personnel to pay the full cost of fund of insurance of primary medical treatment and ginseng protect personnel to share the proportion determined by the region as a whole. The prescribed payment standard shall expire on December 31, 2019 and shall be adjusted according to the relevant provisions of the medical insurance payment standards after the expiry date. Within the validity period, if there is a listing of generic name drugs (generic drugs), the department will adjust the medical insurance payment standard and release it separately according to the price level of the generic drug. If the actual price of the drug market is significantly lower than the current payment standard, the payment standard may be reformulated with the enterprise and shall be published separately. The provinces (autonomous regions and municipalities) should actively explore ways to strengthen drug administration and promote rational use of drugs. To establish a unified pre-examination rule for the provisions requiring "prior examination" or other drugs requiring strict management; The drug should be included in the medical service intelligent monitoring system of basic medical insurance, and the cost analysis should be carried out. Effective measures should be taken to encourage the designated retail pharmacies to provide medicines for insured persons and give play to the positive role of pharmacies in the supply and protection of medical insurance.
Next, the provinces and cities of the category b drug adjustment work will be released as soon as possible, the layout of the enterprise will also follow.
|
